Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
2.
Eur Rev Med Pharmacol Sci ; 24(19): 9899-9907, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-33090393

RESUMO

OBJECTIVE: Long non-coding RNA (lncRNA) maternally expressed 3 (MEG3) has been identified to participate in the progression of malignant tumors. However, the role and function of MEG3 in Wilms' tumor (WT) remain unknown. Therefore, the aim of this study was to detect the role of MEG3 in the development of Wilms' tumor, and to explore the underlying mechanism. PATIENTS AND METHODS: Expression of MEG3 in WT tissues and blood samples were detected using quantitative real-time polymerase chain reaction (qRT-PCR). The relationship between MEG3 level and clinicopathological character and histogenesis was analyzed. WT-CLS1 and WiT49 cells were cultured in vitro, and the influence of ectopic MEG3 expression was determined. Colony formation assay and Edu assay were employed to measure cell proliferation, while transwell assay and Matrigel assay were adopted to detect cell metastasis. Furthermore, Western blot was applied to explore the mechanism of MEG3 in WT. RESULTS: MEG3 was lowly expressed in WT tissues and blood samples (p<0.05). Over-expression of MEG3 significantly reduced the proliferation, invasion and migration of CLS1cells than control cells (p<0.05). However, inhibition of MEG3 in WiT49 cells significantly promoted cell growth and metastasis compared with cells in negative control group (p<0.05). In addition, MEG3 influenced the protein expression of ß-catenin by regulating the Wnt/ß-catenin pathway. CONCLUSIONS: MEG3 was low-expressed in WT tissues and blood samples. Meanwhile, it could inhibit the proliferation and metastasis of WT cells via wt/ß-catenin pathways. All our findings indicated that MEG3 served as a potential target for the diagnosis, treatment and prognosis prediction of WT.


Assuntos
Neoplasias Renais/metabolismo , RNA Longo não Codificante/metabolismo , Tumor de Wilms/metabolismo , beta Catenina/metabolismo , Movimento Celular , Proliferação de Células , Feminino , Humanos , Lactente , Neoplasias Renais/patologia , Masculino , RNA Longo não Codificante/genética , Células Tumorais Cultivadas , Tumor de Wilms/patologia , Via de Sinalização Wnt
4.
Hernia ; 19(5): 697-701, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25431254

RESUMO

PURPOSE: During hernioplasty focal thickened tissue containing smooth muscle is found at the neck of the hernia sac in most patients with indirect inguinal hernia. These thickenings may be related to the processus vaginalis and reveal the etiology of indirect inguinal hernia. METHODS: The study included 50 male adults with indirect inguinal hernia and 50 male adults with direct inguinal hernia, all of them were initial cases. Hernioplasty and excision of the hernia sac were performed, meanwhile anatomical features of the hernia sac and the spermatic cord were recorded, then followed by histological investigation of the hernia sacs. RESULTS: Focal thickenings were observed at the neck of the hernia sac in 88 % of adults with indirect inguinal hernia. Dense adhesion between the hernia sac and the spermatic cord was found where the thickening located. Histological examination identified smooth muscle cells in 57 % of the thickened tissues. No similar findings were observed in patients with direct inguinal hernia. CONCLUSIONS: The focal thickening which contains smooth muscle tissue may be remnant of the processus vaginalis after its obliteration. In other word, the presence of the thickening means that fusion of the processus vaginalis has previously taken place. Thus, most indirect inguinal hernias in adults may represent acquired diseases.


Assuntos
Hérnia Inguinal/etiologia , Hérnia Inguinal/patologia , Herniorrafia/efeitos adversos , Cordão Espermático/patologia , Adulto , Idoso , Hérnia Inguinal/cirurgia , Humanos , Canal Inguinal/patologia , Masculino , Pessoa de Meia-Idade , Músculo Liso/patologia , Peritônio/patologia , Testículo/patologia
5.
Lupus ; 17(7): 638-44, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-18625636

RESUMO

To evaluate the efficacy and safety of leflunomide in the treatment of proliferative lupus nephritis, a prospective multi-centre observational study was conducted. Patients with biopsy proven proliferative lupus nephritis were assigned to receive either leflunomide or cyclophosphamide with concomitant prednisone. Leflunomide was given orally with a loading dose of 1 mg/kg/day for 3 days followed by 30 mg/day. Intravenous cyclophosphamide was administered monthly at a dose of 0.5 g/m2 of body-surface area. A total of 110 patients were enrolled, 70 in the leflunomide group and 40 in the cyclophosphamide group. The complete remission rate in the leflunomide group was 21% and partial remission rate 52%, as compared with 18% and 55%, respectively, in the cyclophosphamide group. Renal parameters and systemic lupus erythematosus disease activity index improved significantly and similarly in both groups. Serum creatinine decreased or stabilized in both treatment groups. No significant difference was noted with respect to clinical outcome between groups. Repeat biopsy also showed a significant reduction of active lesions in kidney pathology after 6 months of leflunomide treatment. Major adverse events, similar in both treatment groups, included infection, alopecia and hypertension. Leflunomide, compared with cyclophosphamide, in combination with prednisone was effective in the induction therapy of proliferative lupus nephritis and was generally well-tolerated.


Assuntos
Imunossupressores/uso terapêutico , Isoxazóis/uso terapêutico , Nefrite Lúpica/tratamento farmacológico , Adolescente , Adulto , Idoso , Biópsia , Progressão da Doença , Feminino , Humanos , Rim/patologia , Rim/cirurgia , Leflunomida , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Resultado do Tratamento
7.
Neuroscience ; 49(3): 557-70, 1992 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-1354337

RESUMO

This study examined the release of endogenous amino acids from acute hippocampal slices, upon stimulation of the Schaffer collateral-commissural fibres. One-minute samples of superfusate were collected via a cannula placed over the CA1 stratum radiatum, and were analysed by reversed-phase high performance liquid chromatography. Evoked potentials were recorded to ascertain stimulation efficacy. Four minutes of continuous 50 Hz stimulation produced a tetrodotoxin-sensitive release of aspartate and glycine in the second minute of stimulation, as well as a tetrodotoxin-sensitive release of cysteine sulphinic acid, during stimulation and of homocysteic acid, following stimulation. Such 50 Hz stimulation also produced a tetrodotoxin-insensitive decrease in methionine levels, but no significant changes in any of the other 15 amino acids measured. Four minutes of continuous 1 Hz stimulation produced no changes in the levels of any of the amino acids measured, but four 600-ms trains of 100 Hz stimulation, which, unlike the 1 Hz stimulation, produced long-term potentiation, resulted in significant increases in levels of cysteine sulphinic acid and homocysteic acid, but not of any of the other amino acids measured. These results suggest that aspartate, glycine, homocysteic acid, and cysteine sulphinic acid play a role in synaptic transmission in the Schaffer collateral-commissural fibres, and that cysteine sulphinic acid and homocysteic acid may be released specifically by high-frequency stimulation.


Assuntos
Aminoácidos/metabolismo , Cisteína/análogos & derivados , Hipocampo/fisiologia , Homocisteína/análogos & derivados , Fibras Nervosas/fisiologia , Animais , Ácido Aspártico/metabolismo , Cisteína/metabolismo , Estimulação Elétrica , Potenciais Evocados , Glutamatos/metabolismo , Ácido Glutâmico , Glicina/metabolismo , Homocisteína/metabolismo , Técnicas In Vitro , Cinética , Masculino , Metionina/metabolismo , Neurotransmissores , Tratos Piramidais/fisiologia , Ratos , Ratos Endogâmicos , Fatores de Tempo , Ácido gama-Aminobutírico/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA